Onexton (Clindamycin Phos/Benzoyl Perox) Patent Expiration, LOE Window & CMS Spending

Onexton (Clindamycin Phos/Benzoyl Perox) by Bausch Health: FDA Orange Book LOE 2029-08-05, 15 AB generics, $319K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN050819 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-08-05
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$319K
2024 Medicare Part D Spend$63K
2024 Medicaid Spend$256K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 22.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.